New preprint: Phase Ib clinical trial of our leading malaria vaccine candidate, RH5.1 in Matrix-M, conducted in Tanzania

Our latest preprint is now available on MedRxiv!

This important Phase Ib clinical trial (NCT04318002), conducted with Dr. Ally Olotu and his team at Ifakara Health Institute, Bagamoyo, Tanzania, assessed our leading clinical vaccine candidate, RH5.1 in Matrix-M^TM in both monthly and delayed dosing regimens in adults and children residing in a malaria-endemic setting for the first time.

The vaccine candidate was shown to be safe and induce highly promising antibody immunogenicity in 5-17 month old children, the target population for a malaria vaccine.

Notably, in the children delayed regimen cohort we report the highest levels of functional growth inhibition activity seen in human trials to date, with all participants in this group achieving target threshold associated with protective outcome in non-human primates. 

These data strongly support onward efficacy assessment of the candidate.

(Photographed Wilmina Kalinga)